Ensysce Biosciences (ENSC) Revenue & Revenue Breakdown
Ensysce Biosciences Revenue Highlights
0
Latest Revenue (Q)
$1.32M
Ensysce Biosciences Revenue by Period
Ensysce Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | -100.00% |
| 2023-12-31 | $2.23M | -11.61% |
| 2022-12-31 | $2.52M | -28.54% |
| 2021-12-31 | $3.53M | -10.18% |
| 2020-12-31 | $3.93M | 122.86% |
| 2019-12-31 | $1.76M | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
Ensysce Biosciences generated - in revenue during NA 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Ensysce Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $1.32M | 1.23% |
| 2024-12-31 | $1.30M | 100.00% |
| 2024-09-30 | - | -100.00% |
| 2024-06-30 | $181.80K | -40.54% |
| 2024-03-31 | $305.72K | -40.64% |
| 2023-12-31 | $515.03K | 18.29% |
| 2023-09-30 | $435.38K | -11.23% |
| 2023-06-30 | $490.47K | -37.89% |
| 2023-03-31 | $789.63K | -44.90% |
| 2022-12-31 | $1.43M | 412.97% |
| 2022-09-30 | $279.35K | 34.65% |
| 2022-06-30 | $207.47K | -65.60% |
| 2022-03-31 | $603.10K | -63.11% |
| 2021-12-31 | $1.64M | 36.14% |
| 2021-09-30 | $1.20M | 170.18% |
| 2021-06-30 | $444.52K | 77.40% |
| 2021-03-31 | $250.58K | -39.84% |
| 2020-12-31 | $416.49K | -49.68% |
| 2020-09-30 | $827.64K | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $862.40K | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | - |
Ensysce Biosciences generated $1.32M in revenue during Q1 2025, up 1.23% compared to the previous quarter, and up 256.29% compared to the same period a year ago.
Ensysce Biosciences Revenue Breakdown
Ensysce Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 |
|---|---|---|
| M P A R | - | $2.01M |
Latest
Quarterly Revenue by Product
| Product/Service | Jun 25 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 |
|---|---|---|---|---|---|---|---|
| MPAR | $1.37M | $119.94K | $437.26K | $481.28K | - | - | - |
| M P A R | - | - | - | - | $1.30M | - | - |
| OUD | - | - | - | - | - | $73.06K | $207.47K |
Latest
Ensysce Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: MPAR (100.00%).
Ensysce Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADXN | Addex Therapeutics | $1.61M | $235.00K |
| SXTP | 60 Degrees Pharmaceuticals | $607.57K | $163.55K |
| VYNE | VYNE Therapeutics | $501.00K | $202.00K |
| SNGX | Soligenix | $119.37K | - |
| SILO | Silo Pharma | $72.10K | $18.03K |
| NLSP | NLS Pharmaceutics | - | - |
| ENSC | Ensysce Biosciences | - | $1.32M |
| CNSP | CNS Pharmaceuticals | - | - |
| KTTA | Pasithea Therapeutics | - | - |